Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05146297 · ClinicalTrials.gov registry record · NA
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
A NA study of Breast Cancer and Prostate Cancer, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- NA
- Development phase
- 644
- Enrollment target
- 3
- Study locations
NCT05146297: Recruiting NA study of Breast Cancer and Prostate Cancer, sponsored by Icahn School of Medicine at Mount Sinai.
NCT05146297 is a NA study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 644 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05146297, a NA study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- NA
- Development phase
- 644 participants
- Enrollment target
- 3
- Study locations
Study Summary
This proposal brings together multidisciplinary teams from four New York City institutions charged with reducing cancer disparities that affect approximately two million people residing in some of the most diverse and underserved communities in the United States. The intent of this collaborative research is captured by its acronym, DISRUPT: Diversity \& IncluSion in Research Underpinning Prevention \& Therapy Trials. To disrupt the norms that maintain heightened risk and poorer outcomes experienced by BIPOC, the research team propose three integrated and synergistic aims to improve diversity and inclusion in CTs through disruptive approaches at the community (Aim 1), provider, system and patient (Aim 2), and basic and translational scientist levels (Aim 3). All three aims focus on metrics for changing norms reified in institutional policies and established practice that will provide essential evidence to translate and scale these changes to institutions and networks involved in cancer treatment research. In Aim 1, the research team will partner with local organizations to formulate and disseminate new norms regarding cancer care and research and diffuse these new norms throughout the community via community organizations and Health Ambassadors bringing a different vantage point on CTs, raising awareness and increasing demand for access to cancer research. In Aim 2, the research team will create an electronic approach to identify key clinical characteristics of patients and trials and match patients and trials and bring these data to patients and their physicians at the time of key decisions. In Aim 3, the research team will provide and integrate essential experiential training in diversity, social determinants of health and the importance of conducting community-relevant work into basic and translational science training. This DISRUPT proposal provides the foundation to disrupt norms about cancer clinical trials in our communities, delivery systems and scientific re
Primary Outcome
Change in rates of clinical trial accrual of the total population and BIPOC population.
Conditions Studied
Interventions
- BEHAVIORAL Clinical trial match-list
- BEHAVIORAL Match-list intervention
Study Locations (3)
New York
- Icahn School of Medicine at Mount Sinai - New York
- Herbert Irving Comprehensive Cancer Care Center - New York
- Albert Einstein College of Medicine - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 644 participants |
| Start Date | 2023-04-23 |
| Est. Completion | 2026-03 |
| Phase | NA |
What NCT05146297 shows while recruiting
NCT05146297 is an interventional study that assigns participants to a tested intervention. The registered 644 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (77% lower).
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Clinical trial match-list is the first listed.
NCT05146297 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05146297 about?
NCT05146297 is a clinical study titled "Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials". This proposal brings together multidisciplinary teams from four New York City institutions charged with reducing cancer disparities that affect approximately two million people residing in some of the most diverse and underserved communities in the United States. The intent of this collaborative res...
What is the current status of trial NCT05146297?
This trial is currently recruiting. It is a NA study. The enrollment target is 644 participants. The study started on 2023-04-23. Estimated completion is 2026-03.
What conditions does trial NCT05146297 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Liver Cancer.
What interventions are being tested in trial NCT05146297?
The interventions under investigation include: Clinical trial match-list (BEHAVIORAL), Match-list intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05146297?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05146297 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05146297's enrollment target sits among peer trials
644 169th of 1224 higher than 1,055 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06994442 · 644 participants · Phase 3
Optimizing Pain Treatment in Children On Mechanical Ventilation
- NCT07012395 · 645 participants · Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- NCT04863222 · 646 participants · Phase 4
Clinical and Radiographic Success of MTA vs Biodentine
- NCT05204888 · 642 participants · NA
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI